3C-TFE, also known as 4-(2,2,2-trifluoroethoxy)-3,5-dimethoxyamphetamine or as ñ-methyltrifluoroescaline (3C-trifluoroescaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA; 3C-M). It is a trifluorinated derivative of 3C-E. The drug's dose is 30mg and its duration is approximately 15hours. It shows weak but significant affinity for the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 1,825nM and 1,659nM, respectively). 3C-TFE was first described in the scientific literature by Daniel Trachsel in 2002. The pharmacology of a number of 3C drugs was studied in 2021, but 3C-TFE was not one of the included compounds. It is a controlled substance in Canada as an analogue of amphetamine.